Interferon Side Effects: What Studies Report

What the literature means by "interferon"

Interferons are signalling proteins of the innate immune system. In the clinical literature the word covers several different things at once, and that matters for anyone reading about tolerability. It covers recombinant and pegylated interferon alfa products given as treatment, interferon delivered locally to a tumour by gene therapy, and, in a mirror-image body of work, drugs designed to block interferon signalling. The adverse-event profile described in a paper therefore depends entirely on which of those situations was studied. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question or treatment decision.

Because interferon alfa products are approved prescription biologics in several jurisdictions, much of the tolerability evidence comes from regulated trials and from clinical reviews written for prescribers rather than from small exploratory studies. Research-grade peptide and protein materials sold for laboratory use are labelled research-use-only and are not the same as the licensed products evaluated in the trials summarised below.

Side-effect management in interferon-based regimens: What Studies Report

The most concentrated discussion of interferon tolerability sits in the hepatology literature, where interferon-based antiviral regimens were used for years before direct-acting agents. A 2011 review published in Clinics and Research in Hepatology and Gastroenterology was devoted specifically to the management of side-effects arising during those regimens, treating symptom management as inseparable from the ability to complete a course of therapy (PMID 22248698). The review is a management-oriented synthesis rather than a single trial, and researchers framed side-effect handling as an ongoing clinical task across the treatment period (PMID 22248698).

That framing is a useful reminder of how interferon safety data are usually presented: not as a single headline event rate, but as a catalogue of tolerability issues that clinicians monitored and managed. Readers looking for one number that summarises "interferon side effects" will not find it in the cited literature, because the reported profile varies by product, route, indication and the drugs given alongside it.

Combination regimens and overlapping toxicity: What Studies Report

When interferon is combined with another agent, the reported adverse-event picture reflects both drugs. A 2020 analysis in Computational and Mathematical Methods in Medicine assessed the potential adverse events related to a ribavirin–interferon combination that had been proposed for novel coronavirus therapy, using computational and mathematical methods rather than a prospective clinical cohort (PMID 33029193). The study is an example of a broader point in the literature: researchers examining repurposed interferon combinations have looked explicitly at whether toxicities from the two components overlap or compound (PMID 33029193).

The hepatitis D literature illustrates the same theme from the other direction. A 2021 report in Terapevticheskii Arkhiv evaluated the efficacy and safety of bulevirtide in patients with chronic hepatitis D and compensated cirrhosis, a population in which interferon-based therapy had long been one of the few available options (PMID 36286651). Papers of that kind are relevant to interferon tolerability mainly as comparators: researchers reported on newer agents in settings where interferon exposure and its tolerability burden had been part of the standard of care (PMID 36286651).

Cardiac findings: What Studies Report

Cardiac effects have been studied as a discrete question. A 2016 paper in the Journal of Ayub Medical College, Abbottabad was titled and designed around the effects of interferon therapy on the heart, examining cardiac outcomes in patients receiving interferon (PMID 28718534). The study sits in the smaller category of organ-specific interferon safety work, where researchers looked at one system in detail rather than tabulating all adverse events (PMID 28718534). Its size and single-centre design limit how far the findings generalise, and the paper does not establish causation for any individual patient.

Haematology settings: What Studies Report

Interferon alfa has a long history in myeloproliferative neoplasms, and the tolerability discussion there is distinct from the hepatitis literature. A 2023 Japanese review in Rinsho Ketsueki addressed interferon therapy for polycythaemia vera, covering its role and the practical considerations around its use (PMID 37914244). Reviews of this type place interferon alongside cytoreductive alternatives, and researchers discussed long-term therapy in a chronic, non-curative disease context (PMID 37914244).

In essential thrombocythaemia, the SURPASS-ET programme was designed as a phase III comparison of ropeginterferon alfa-2b against anagrelide as second-line therapy, with the trial protocol published in Future Oncology in 2022 (PMID 35924546). Head-to-head designs like this one are the most informative source of comparative tolerability information, because both arms are monitored under the same protocol; researchers set out efficacy and safety endpoints in advance rather than collecting adverse events retrospectively (PMID 35924546). The published protocol does not itself contain outcome results, and readers should treat design papers and results papers as different kinds of evidence.

Locally delivered interferon: What Studies Report

Route of delivery changes the safety question. A phase 1 trial published in Nature Medicine evaluated tumour-targeted interferon-α gene therapy for glioblastoma, with the early-phase design placing safety and tolerability among its central objectives (PMID 42225991). Phase 1 oncology trials are small and are not designed to estimate the frequency of uncommon events, so the study reported on a limited number of participants under intensive monitoring (PMID 42225991). Findings from a locally delivered gene-therapy construct cannot be mapped onto systemically injected interferon products, and the cited paper does not make that claim.

Blocking interferon signalling: What Studies Report

A second and often confused body of literature concerns drugs that inhibit interferon activity. Anifrolumab is a monoclonal antibody targeting the type I interferon receptor, and its development programme generated several safety-focused publications. A 2018 study in Lupus Science & Medicine assessed the safety, tolerability and pharmacokinetics of subcutaneous and intravenous anifrolumab in healthy volunteers, comparing the two routes within a single programme (PMID 29644080). A multicentre, phase 2, open-label study published in Modern Rheumatology then examined safety and tolerability in Japanese patients with systemic lupus erythematosus (PMID 30793642).

Longer-term data came from a randomised, placebo-controlled phase III extension trial reported in Arthritis & Rheumatology in 2023, which was designed specifically to characterise long-term safety and tolerability in active systemic lupus erythematosus rather than to test a new efficacy hypothesis (PMID 36369793). Extension trials of that design matter because they follow participants beyond the original treatment period, and researchers reported tolerability against a placebo comparator over the extended window (PMID 36369793).

Interferon-gamma has its own blockade literature. A 2024 analysis in Pediatric Blood & Cancer examined the exposure–safety relationship in patients with primary haemophagocytic lymphohistiocytosis treated with emapalumab, an anti-interferon-gamma antibody, asking whether drug exposure tracked with safety outcomes (PMID 38014905). Exposure–response analyses of this type are pharmacometric rather than purely descriptive, and researchers used modelled exposure rather than nominal dose as the explanatory variable (PMID 38014905).

Further upstream, a phase 1b randomised, double-blind, placebo-controlled study in ACR Open Rheumatology reported the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of afimetoran, a Toll-like receptor 7 and 8 inhibitor, in patients with cutaneous lupus erythematosus (PMID 40568766). TLR7/8 signalling sits upstream of type I interferon production, so the study belongs to the same conceptual family as the receptor-blocking work even though it does not involve interferon administration (PMID 40568766).

How the cited studies differ

What this literature does not establish

Several limits are visible across the cited papers. First, the reported profiles are indication-specific: findings from a review of interferon-based hepatitis therapy (PMID 22248698) are not interchangeable with findings from a phase 1 glioblastoma gene-therapy trial (PMID 42225991). Second, healthy-volunteer data are scarce and, where they exist in this set, relate to an interferon-receptor blocker rather than to interferon itself (PMID 29644080). Third, design and protocol publications such as the SURPASS-ET paper describe planned endpoints rather than results (PMID 35924546).

Fourth, none of the cited work addresses non-clinical or unsupervised use of interferon-like materials, and no paper in this set reports outcomes for people using research-labelled products outside a trial. Fifth, terminology confusion is common: blocking type I interferon signalling (PMID 36369793) and blocking interferon-gamma (PMID 38014905) are opposite interventions to giving interferon, and their safety findings should not be read as interferon side-effect data.

For the underlying biology, receptor families and the history of interferon as a therapeutic class, PeptideU's interferon course in the Learn section covers the mechanism material that this safety-focused page does not. This page remains educational only and is not medical advice; decisions about any interferon product belong with a licensed physician.

References

• Management of side-effects (Clinics and Research in Hepatology and Gastroenterology, 2011)
• Assessment of the Potential Adverse Events Related to Ribavirin-Interferon Combination for Novel Coronavirus Therapy (Computational and Mathematical Methods in Medicine, 2020)
• Effects Of Interferon Therapy On Heart (Journal of Ayub Medical College, Abbottabad, 2016)
• [Interferon therapy for polycythemia vera] (Rinsho Ketsueki, 2023)
• SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia (Future Oncology, 2022)
• Tumor-targeted interferon-α gene therapy for glioblastoma: a phase 1 trial (Nature Medicine, 2026)
• Safety, tolerability and pharmacokinetics of subcutaneous and intravenous anifrolumab in healthy volunteers (Lupus Science & Medicine, 2018)
• Safety and tolerability of anifrolumab, a monoclonal antibody targeting type I interferon receptor, in Japanese patients with systemic lupus erythematosus: A multicenter, phase 2, open-label study (Modern Rheumatology, 2020)
• A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus (Arthritis & Rheumatology, 2023)
• Exposure-safety relationship for patients with primary hemophagocytic lymphohistiocytosis treated with emapalumab (Pediatric Blood & Cancer, 2024)
• Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Afimetoran, a Toll-Like Receptor 7 and 8 Inhibitor, in Patients With Cutaneous Lupus Erythematosus: A Phase 1b Randomized, Double-Blind, Placebo-Controlled Study (ACR Open Rheumatology, 2025)
• [Efficacy and safety of bulevirtide in patients with chronic hepatitis D and compensated cirrhosis] (Terapevticheskii Arkhiv, 2021)